View Clinical Trial (Medical Research Study)

Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea - NCT00936481-37232(Clinical Trial 301324)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Nashville
State:  
TN
Zip Code: 37232
Conditions: Obstructive Sleep Apnea
Purpose: Obstructive sleep apnea is a condition in which people have decreased breathing during their sleep. Untreated sleep apnea has been linked to increased risk for cardiovascular diseases. This research study is looking at blood clotting factors and blood vessel function in health volunteers and patients with newly diagnosed or untreated obstructive sleep apnea to better understand the underlying mechanisms for increased cardiovascular risk.
Study summary: Cardiovascular disease (CVD), which includes strokes, has been the number one killer in the United States.Each year about 700,000 people experience a new or recurrent stroke, which translates into about one stroke every 45 seconds. Apart from traditional risk factors for stroke such as hypertension, smoking and atrial fibrillation, obstructive sleep apnea is now being increasingly recognized as another important treatable risk factor. The majority of strokes and myocardial infarctions are due to atherothrombotic events. Impaired fibrinolytic activity increases the propensity for thromboembolic events. Many different candidate molecules have been studied as the cause of a hypercoagulable state. Plasminogen Activator Inhibitor-1 (PAI-1) is the major physiologic inhibitor of the body's fibrinolytic system including the principal serine protease tissue-type plasminogen activator (t-PA). It is therefore poised to be a pivotal regulator of the fibrinolytic system.Recent studies have shown that PAI-1 levels are elevated in patients with obstructive sleep apnea (OSA) and that PAI-1 levels correlate with severity of OSA. The purpose of this pilot study is twofold: - To characterize changes in the blood levels of plasminogen activator inhibitor-1 (PAI-1) and tissue type plasminogen activator ( t-PA) across the 24 hour cycle in patients with obstructive sleep apnea, as compared to normal controls, and to further identify the pattern of changes with varying severity of obstructive sleep apnea, and - To study endothelial function in patients with obstructive sleep apnea, as compared to normal controls. Data gathered from this pilot study will be used to initiate a more comprehensive prospective study exploring the link between OSA, endothelial function, the fibrinolytic system and cardiovascular events. This area can be further explored by prospectively following patients to assess for a reduction in such events with treatment of OSA.
Criteria: Inclusion Criteria: - Age 18 years or older. - Subjects are able and willing to provide informed consent. - Subjects are willing to cooperate with polysomnography and have serial blood draws over a 24-hour period. - Evidence for OSA (AHI>5 events/hour) without treatment or suspected OSA based on symptoms in the patient group. - Body mass index of 25-45 Exclusion Criteria: - History of myocardial infarction, stroke or transient ischemic attack (TIA) or peripheral vascular disease. - History of chronic diseases such as diabetes mellitus, uncontrolled hypertension (SBP >160, DBP > 120), renal failure on dialysis, cancer, autoimmune or liver disease. - A significant history of medical or psychiatric disease that may impair participation in the trial. - Evidence of medical instability (cardiac arrhythmias, congestive heart failure, pulmonary disease) that require an expedited evaluation and treatment of the OSA. - History of alcohol, or drug abuse during the one-year-period prior to trial participation. - Current use of tobacco products. - Current treatment with angiotensin converting enzyme-inhibitors and or chronic use of non-steroidal anti-inflammatory agents. - Another primary sleep disorder that requires intervention with medications or cause disrupted sleep. - Patients with unusual sleep or wake habits, including shift work. - Transmeridian travel in the previous 3 months. - Patients with OSA who have already received treatment with CPAP, surgery or oral appliance. - Pregnancy; as hormonal changes affect sleep disordered breathing.
Study is available at: Vanderbilt University Medical Center,Department of Neurology
Nashville, TN 37232
United States

Primary Contact:
Kanika Bagai, M.D
Email: kanika.bagai@vanderbilt.edu
Phone: 615-322-0283

Secondary Contact:
Kanika Bagai, M.D.
Email: kanika.bagai@vanderbilt.edu
Phone: 615-322-0283
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.